Beutel, Goodman & CO Ltd. Amgen Inc Transaction History

Beutel, Goodman & CO Ltd.

$20.3 Billion
Q3 2024

A detailed history of Beutel, Goodman & CO Ltd. transactions in Amgen Inc stock. As of the latest transaction made, Beutel, Goodman & CO Ltd. holds 1,099,883 shares of AMGN stock, worth $290 Million. This represents 1.75% of its overall portfolio holdings.

Number of Shares

1,099,883

Previous 1,673,291 34.27%

Holding current value

$290 Million

Previous $523 Million 32.21%

% of portfolio

1.75%

Previous 2.78%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$309.38 - $337.38 $177 Million - $193 Million	-573,408 Reduced 34.27%	1,099,883 $354 Million
Q2 2024 Aug 13, 2024	BUY	$262.75 - $319.31 $21.6 Million - $26.2 Million	82,036 Added 5.16%	1,673,291 $523 Million
Q1 2024 May 14, 2024	BUY	$268.87 - $324.56 $5.81 Million - $7.01 Million	21,598 Added 1.38%	1,591,255 $452 Million
Q4 2023 Feb 09, 2024	SELL	$255.7 - $288.46 $1.53 Million - $1.73 Million	-5,985 Reduced 0.38%	1,569,657 $452 Million
Q3 2023 Nov 13, 2023	SELL	$218.65 - $271.46 $65,595 - $81,438	-300 Reduced 0.02%	1,575,642 $423 Million
Q2 2023 Aug 14, 2023	BUY	$214.27 - $253.37 $43.8 Million - $51.8 Million	204,486 Added 14.91%	1,575,942 $350 Million
Q1 2023 May 12, 2023	BUY	$225.79 - $275.2 $6.36 Million - $7.75 Million	28,165 Added 2.1%	1,371,456 $332 Million
Q4 2022 Feb 14, 2023	SELL	$229.03 - $291.01 $45.3 Million - $57.6 Million	-197,888 Reduced 12.84%	1,343,291 $353 Million
Q3 2022 Nov 14, 2022	SELL	$224.46 - $253.15 $28.9 Million - $32.6 Million	-128,762 Reduced 7.71%	1,541,179 $347 Million
Q2 2022 Aug 15, 2022	BUY	$230.71 - $256.74 $11.2 Million - $12.5 Million	48,505 Added 2.99%	1,669,941 $406 Million
Q1 2022 May 12, 2022	BUY	$219.27 - $242.57 $10.1 Million - $11.2 Million	46,105 Added 2.93%	1,621,436 $392 Million
Q4 2021 Feb 14, 2022	BUY	$198.88 - $227.6 $19.4 Million - $22.2 Million	97,584 Added 6.6%	1,575,331 $354 Million
Q3 2021 Nov 12, 2021	BUY	$212.27 - $248.7 $25.3 Million - $29.6 Million	119,022 Added 8.76%	1,477,747 $314 Million
Q2 2021 Aug 13, 2021	BUY	$233.58 - $259.14 $34.4 Million - $38.2 Million	147,292 Added 12.16%	1,358,725 $331 Million
Q1 2021 May 14, 2021	BUY	$221.91 - $258.6 $40.5 Million - $47.2 Million	182,472 Added 17.73%	1,211,433 $301 Million
Q4 2020 Feb 05, 2021	BUY	$216.38 - $257.67 $89.4 Million - $106 Million	412,976 Added 67.04%	1,028,961 $237 Million
Q3 2020 Nov 13, 2020	SELL	$234.65 - $260.95 $57.1 Million - $63.5 Million	-243,516 Reduced 28.33%	615,985 $157 Million
Q2 2020 Aug 14, 2020	SELL	$197.81 - $242.74 $21.8 Million - $26.7 Million	-109,996 Reduced 11.35%	859,501 $203 Million
Q1 2020 May 14, 2020	SELL	$182.24 - $241.7 $15 Million - $19.8 Million	-82,117 Reduced 7.81%	969,497 $197 Million
Q4 2019 Feb 24, 2020	SELL	$189.21 - $243.2 $26.7 Million - $34.3 Million	-140,984 Reduced 11.82%	1,051,614 $254 Million
Q4 2019 Feb 14, 2020	BUY	$189.21 - $243.2 $25.8 Million - $33.1 Million	136,214 Added 12.89%	1,192,598 $287 Million
Q3 2019 Oct 31, 2019	SELL	$174.11 - $208.62 $7.68 Million - $9.21 Million	-44,127 Reduced 4.01%	1,056,384 $17.7 Million
Q2 2019 Aug 15, 2019	BUY	$166.7 - $195.41 $61.5 Million - $72.1 Million	369,142 Added 50.47%	1,100,511 $0
Q1 2019 Apr 26, 2019	BUY	$180.87 - $203.88 $11.9 Million - $13.4 Million	65,821 Added 9.89%	731,369 $104 Million
Q4 2018 Feb 07, 2019	BUY	$178.4 - $208.25 $10.1 Million - $11.7 Million	56,365 Added 9.25%	665,548 $9.49 Million
Q3 2018 Oct 31, 2018	SELL	$185.29 - $208.89 $1.55 Million - $1.74 Million	-8,347 Reduced 1.35%	609,183 $97.7 Million
Q2 2018 Jul 30, 2018	BUY	$166.05 - $186.51 $103 Million - $115 Million	617,530 New	617,530 $86.7 Million

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Beutel, Goodman & CO Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Beutel, Goodman & CO Ltd. with notifications on news.

Account

Beutel, Goodman & CO Ltd. Amgen Inc Transaction History